Incyte Corporation
GB ˙ LSE ˙ US45337C1027
104,35 $ ↑3,62 (3,59%)
2026-06-05
DEL PRIS
SecurityGB:0J9P / Incyte Corporation
InstitutionCrossmark Global Holdings, Inc.
Latest Disclosed Ownership83,415 shares
Latest Disclosed Value $ 7,851,019
Crossmark Global Holdings, Inc. reports 3.26% increase in ownership of 0J9P / Incyte Corporation

On May 11, 2026 - Crossmark Global Holdings, Inc. filed a 13F-HR form disclosing ownership of 83,415 shares of Incyte Corporation (GB:0J9P) valued at $7,779,283 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 3, 2026 disclosing 80,784 shares of Incyte Corporation. This represents a change in shares of 3.26% during the quarter. The current value of the position is $8,704,355 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F INCYTE COM 45337C102 83,415 2,631 3.26 7,851 -1.60 0.1147
2026-02-03 2025-12-31 13F INCYTE COM 45337C102 80,784 6,964 9.43 7,979 27.46 0.1138
2025-11-12 2025-09-30 13F INCYTE COM 45337C102 73,820 -3,197 -4.15 6,261 19.37 0.0938
2025-08-08 2025-06-30 13F INCYTE COM 45337C102 77,017 27,167 54.50 5,245 73.76 0.0847
2025-04-30 2025-03-31 13F INCYTE COM 45337C102 49,850 -128 -0.26 3,018 100,500.00 0.0532
2025-01-16 2024-12-31 13F INCYTE GENOMICS COM 45337C102 49,978 24,899 99.28 3 200.00 0.0629
2024-11-04 2024-09-30 13F INCYTE GENOMICS COM 45337C102 25,079 276 1.11 2 0.00 0.0296
2024-07-29 2024-06-30 13F INCYTE GENOMICS COM 45337C102 24,803 -3,176 -11.35 2 0.00 0.0287
2024-05-13 2024-03-31 13F INCYTE GENOMICS COM 45337C102 27,979 -4,615 -14.16 2 -50.00 0.0306
2024-02-13 2023-12-31 13F INCYTE GENOMICS COM 45337C102 32,594 -961 -2.86 2 100.00 0.0425
2023-11-08 2023-09-30 13F INCYTE GENOMICS COM 45337C102 33,555 8,366 33.21 2 0.00 0.0435
2023-07-31 2023-06-30 13F INCYTE GENOMICS COM 45337C102 25,189 -19,072 -43.09 2 -66.67 0.0342
2023-05-12 2023-03-31 13F INCYTE GENOMICS COM 45337C102 44,261 18,117 69.30 3 50.00 0.0753
2023-01-19 2022-12-31 13F INCYTE GENOMICS COM 45337C102 26,144 -1,275 -4.65 2 -99.89 0.0523
2022-11-01 2022-09-30 13F INCYTE GENOMICS COM 45337C102 27,419 6,508 31.12 1,828 15.04 0.0507
2022-07-29 2022-06-30 13F INCYTE GENOMICS COM 45337C102 20,911 1,500 7.73 1,589 3.11 0.0412
2022-05-11 2022-03-31 13F INCYTE GENOMICS COM 45337C102 19,411 790 4.24 1,541 12.73 0.0344
2022-01-10 2021-12-31 13F INCYTE GENOMICS COM 45337C102 18,621 -20 -0.11 1,367 6.63 0.0297
2021-10-21 2021-09-30 13F/A-1 INCYTE GENOMICS COM 45337C102 18,641 640 3.56 1,282 -15.32 0.0300
2021-07-21 2021-06-30 13F INCYTE GENOMICS COM 45337C102 18,001 350 1.98 1,514 5.58 0.0356
2021-04-15 2021-03-31 13F INCYTE GENOMICS COM 45337C102 17,651 -1,130 -6.02 1,434 -12.24 0.0355
2021-01-14 2020-12-31 13F INCYTE GENOMICS COM 45337C102 18,781 -9,630 -33.90 1,634 -35.92 0.0413
2020-10-08 2020-09-30 13F INCYTE GENOMICS COM 45337C102 28,411 704 2.54 2,550 -11.49 0.0715
2020-08-14 2020-06-30 13F INCYTE GENOMICS COM 45337C102 27,707 -1,940 -6.54 2,881 32.70 0.0840
2020-04-28 2020-03-31 13F INCYTE GENOMICS COM 45337C102 29,647 931 3.24 2,171 -13.40 0.0777
2020-02-06 2019-12-31 13F INCYTE GENOMICS COM 45337C102 28,716 15,249 113.23 2,507 150.70 0.0689
2019-10-09 2019-09-30 13F INCYTE GENOMICS COM 45337C102 13,467 -406 -2.93 1,000 -15.18 0.0292
2019-07-09 2019-06-30 13F INCYTE GENOMICS COM 45337C102 13,873 -8 -0.06 1,179 -1.26 0.0331
2019-05-02 2019-03-31 13F INCYTE GENOMICS COM 45337C102 13,881 -88 -0.63 1,194 34.46 0.0339
2019-01-31 2018-12-31 13F INCYTE GENOMICS COM 45337C102 13,969 -5,510 -28.29 888 -34.03 0.0275
2018-11-08 2018-09-30 13F/A-1 INCYTE GENOMICS COM 45337C102 19,479 -442 -2.22 1,346 0.82 0.0342
2018-11-06 2018-09-30 13F INCYTE GENOMICS COM 45337C102 19,921 0 1,335
2018-07-31 2018-06-30 13F INCYTE GENOMICS COM 45337C102 19,921 -470 -2.30 1,335 -21.42 0.0358
2018-04-16 2018-03-31 13F INCYTE GENOMICS COM 45337C102 20,391 -792 -3.74 1,699 -15.30 0.0439
2018-02-05 2017-12-31 13F INCYTE GENOMICS COM 45337C102 21,183 283 1.35 2,006 -17.79 0.0482
2017-10-27 2017-09-30 13F INCYTE GENOMICS COM 45337C102 20,900 0 0.00 2,440 0.00 0.0629
2017-10-25 2016-09-30 13F INCYTE GENOMICS COM 45337C102 20,900 20,900 2,440 0.0629
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.